WO2022017449A1 - 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 - Google Patents
一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 Download PDFInfo
- Publication number
- WO2022017449A1 WO2022017449A1 PCT/CN2021/107815 CN2021107815W WO2022017449A1 WO 2022017449 A1 WO2022017449 A1 WO 2022017449A1 CN 2021107815 W CN2021107815 W CN 2021107815W WO 2022017449 A1 WO2022017449 A1 WO 2022017449A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- compound
- formula
- solvent
- cancer
- Prior art date
Links
- RXNPEQZHMGFNAY-GEALJGNFSA-N CC(C)NC[C@@H](C(N(CC1)[C@H](C2)[C@H]2N1c1ncnc(N2)c1[C@H](C)CC2=O)=O)c(cc1)ccc1Cl Chemical compound CC(C)NC[C@@H](C(N(CC1)[C@H](C2)[C@H]2N1c1ncnc(N2)c1[C@H](C)CC2=O)=O)c(cc1)ccc1Cl RXNPEQZHMGFNAY-GEALJGNFSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the application belongs to the field of medicinal chemistry, and in particular relates to a salt of a dihydropyrido[2,3-d]pyrimidinone derivative, a preparation method thereof, and a medicinal use thereof.
- PI3K/AKT/mTOR pathway composed of phosphatidylinositol 3-kinase (PI3K) and its downstream protein AKT (also known as protein kinase B, PKB) and mammalian target of rapamycin (mTOR) is very important in cells.
- Signal transduction pathway plays an extremely important biological function in the process of cell growth, survival, proliferation, apoptosis, angiogenesis, and autophagy. Aberrant activation of this pathway causes a range of diseases, including cancer, neuropathy, autoimmune diseases, and hemolymphatic disorders.
- AKT a class of serine/threonine kinases, affects cell survival, growth, metabolism, proliferation, migration and differentiation through numerous downstream effectors.
- AKT overactivation especially prostate cancer, pancreatic cancer, bladder cancer, ovarian cancer, and breast cancer. AKT overactivation can lead to tumorigenesis, metastasis and drug resistance.
- AKT has three subtypes: AKT1, AKT2, and AKT3.
- each isoform consists of an amino-terminal PH domain (Pleckstrin homology domain), a central ATP-binding kinase domain, and a carboxy-terminal regulatory domain.
- About 80% of the amino acid sequences of the three isoforms are homologous, and only the PH domain and the kinase domain link region vary greatly.
- the targeted drugs for the PI3K/AKT/mTOR signaling pathway are mainly PI3K inhibitors and mTOR inhibitors, and AKT is at the core of this signal transduction pathway. Inhibition of AKT activity can not only avoid the serious side effects caused by the inhibition of upstream PI3K, but also avoid the negative feedback mechanism caused by the inhibition of downstream mTOR.
- CN101631778A discloses a class of cyclopentadieno[D]pyrimidine derivatives
- CN101578273A discloses a class of hydroxylated and methoxylated cyclopentadieno[D]pyrimidine derivatives
- CN101511842A discloses a class of two tetrahydrofuran and pyrimidine derivatives
- CN101970415A discloses a class 5H- cyclopenta [d] pyrimidine derivatives
- these compounds have IC 50 of less than 10 ⁇ M in AKT1 inhibition.
- the search for effective and selective AKT inhibitors is still an important direction of current tumor-targeted drug development.
- the application provides a pharmaceutically acceptable salt of a compound of formula 1, the salt is selected from an organic acid salt or an inorganic acid salt, wherein the organic acid salt is selected from the group consisting of fumarate, mesylate, hydroxyethanesulfonate acid salt, ⁇ -naphthalene sulfonate, p-toluenesulfonate, 1,2-ethanedisulfonate, oxalate, maleate, citrate, succinate, L-(+)-tartaric acid Salt, hippurate, L-ascorbate, L-malate, benzoate or gentisate, the inorganic acid salt is selected from hydrochloride, sulfate or phosphate, the structure of the compound of formula 1 is as follows :
- the organic acid salt is selected from fumarate salts.
- the inorganic acid salt is selected from hydrochloride salts.
- the molar ratio of the compound of formula 1 to the organic acid in the organic acid salt is 1:1.
- the molar ratio of the compound of formula 1 to hydrogen chloride in the hydrochloride salt is 1:1 or 1:2.
- the molar ratio of the compound of formula 1 to hydrogen chloride in the hydrochloride salt is 1:2.
- the molar ratio of the compound of formula 1 to sulfuric acid in the sulfate salt is 1:1.
- the molar ratio of the compound of formula 1 to phosphoric acid in the phosphate is 1:1.
- the salt mentioned in this application is obtained by the salt-forming reaction between the compound of formula 1 and the corresponding acid.
- the compound of formula 1 is converted into a cation and combined with the acid radical of the corresponding acid to form the salt;
- the molar ratio of the compound of formula 1 to the acid in the application can be understood as the molar ratio of the cation of the compound of formula 1 to the acid radical of the corresponding acid in the salt.
- the application provides a fumarate salt of a compound of formula 1, wherein the molar ratio of the compound of formula 1 to fumaric acid is 1:1, or the moles of the cation of the compound of formula 1 to the acid radical of fumaric acid The ratio is 1:1.
- the application provides a hydrochloride salt of a compound of formula 1, wherein the molar ratio of the compound of formula 1 to hydrogen chloride is 1:1, or the molar ratio of the cation of the compound of formula 1 to chloride ion is 1:1, In this case it is the monohydrochloride salt of the compound of formula 1 .
- the application provides the hydrochloride salt of the compound of formula 1, wherein the molar ratio of the compound of formula 1 to hydrogen chloride is 1:2, or the molar ratio of the cation of the compound of formula 1 to chloride ion is 1:2, In this case it is the dihydrochloride salt of the compound of formula 1 .
- the present application provides a method for the preparation of a pharmaceutically acceptable salt of a compound of formula 1, comprising the step of forming a salt of the compound of formula 1 with a corresponding acid.
- the solvent for the salt-forming reaction is selected from a mixed solvent of an alcohol-based solvent and an alkane-based solvent, a mixed solvent of a ketone-based solvent and an alkane-based solvent, a mixed solvent of an ester-based solvent and an alkane-based solvent, a benzene-based solvent Mixed solvent of solvent and alkane solvent or mixed solvent of halogenated hydrocarbon solvent and alkane solvent.
- the alcoholic solvent is selected from methanol, ethanol or isopropanol; preferably isopropanol; the ketone solvent is selected from acetone or butanone; preferably acetone; the ester solvent is selected from ethyl acetate ester or butyl acetate; preferably ethyl acetate; the benzene-based solvent is selected from toluene; the halogenated hydrocarbon-based solvent is selected from methylene chloride; the alkane-based solvent is selected from n-heptane.
- the present application provides a method for preparing a fumarate salt of a compound of formula 1, comprising the step of salifying the compound of formula 1 with fumaric acid; preferably, the salt-forming solvent is selected from isopropanol and n-heptane alkane mixed solvent.
- the present application provides a method for preparing the hydrochloride of the compound of formula 1, comprising the step of salifying the compound of formula 1 with hydrochloric acid; preferably, the salt-forming solvent is selected from a mixed solvent of toluene and n-heptane or A mixed solvent of ethyl acetate and n-heptane.
- the present application also provides a pharmaceutical composition comprising the pharmaceutically acceptable salt of the compound of formula 1.
- the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition is a solid pharmaceutical formulation suitable for oral administration, preferably a tablet or capsule.
- the present application also provides a pharmaceutically acceptable salt of the compound of formula 1 or a pharmaceutical composition thereof for use as a medicament.
- the present application also provides the use of a pharmaceutically acceptable salt of the compound of formula 1 or a pharmaceutical composition thereof in the manufacture of a medicament for preventing and/or treating AKT protein kinase-mediated diseases or disease states.
- the present application also provides the use of a pharmaceutically acceptable salt of the compound of formula 1 or a pharmaceutical composition thereof for preventing and/or treating a disease or disease state mediated by AKT protein kinase.
- the application also provides a method for preventing and/or treating an AKT protein kinase-mediated disease or disease state, comprising administering to an individual in need thereof a pharmaceutically acceptable salt of a compound of formula 1 of the application or its pharmaceutical composition.
- the present application also provides a pharmaceutically acceptable salt of the compound of formula 1 of the present application or a pharmaceutical composition thereof for use in the prevention and/or treatment of AKT protein kinase mediated diseases or disease states.
- the AKT protein kinase-mediated disease or disease state is cancer.
- the cancer is breast cancer, prostate cancer, or ovarian cancer.
- the cancer is prostate cancer.
- the pharmaceutically acceptable salts of the present application also include their hydrate forms.
- pharmaceutically acceptable carrier refers to those carriers which are not significantly irritating to the body and which do not impair the biological activity and properties of the active compound. Including but not limited to any diluent, disintegrant, binder, glidant, wetting agent approved by the State Food and Drug Administration for human or animal use.
- fumaric acid refers to fumaric acid, which has the structure:
- alcoholic solvent refers to a substance derived from one or more hydroxyl groups (OH) substituted for one or more hydrogen atoms on a C1-C6 alkane
- the C1-C6 alkane refers to a substance containing 1-6 carbon atoms.
- Specific examples of straight-chain or branched-chain alkanes and alcohol solvents include, but are not limited to, methanol, ethanol, isopropanol or n-propanol.
- alkane-based solvent refers to straight-chain or branched-chain or cyclic alkanes containing 5-7 carbon atoms, and specific examples include, but are not limited to, n-hexane, cyclohexane, and n-heptane.
- ester solvent refers to a chain compound containing an ester group -COOR and having 3-10 carbon atoms, wherein R is a C1-C6 alkyl group, and the C1-C6 alkyl group refers to a chain compound containing 1-6 carbon atoms.
- Specific examples of the linear or branched alkanes of carbon atoms, and ester-based solvents include, but are not limited to, methyl acetate, ethyl acetate, and propyl acetate.
- halogenated hydrocarbon solvent refers to a substance derived by replacing one or more hydrogen atoms on a C1-C6 alkane with one or more halogen atoms
- the C1-C6 alkane refers to a solvent containing 1-6 carbon atoms.
- Straight-chain or branched-chain alkane the halogen atom refers to fluorine, chlorine, bromine, iodine
- specific examples of halogenated hydrocarbon solvents include, but are not limited to, dichloromethane or chloroform.
- ketone solvent refers to a chain or cyclic compound containing carbonyl-CO- and having 3-10 carbon atoms, and specific examples include but are not limited to acetone, butanone or cyclohexanone.
- benzene-based solvent refers to a solvent containing a phenyl group, and specific examples include toluene, xylene, cumene, or chlorobenzene.
- equivalent refers to the equivalent amount of other raw materials required according to the equivalent relationship of the chemical reaction, taking the basic raw material used in each step as 1 equivalent.
- HATU 2-(7-Azobenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate
- TK tyrosine kinase
- Fig. 1 is the single molecule schematic diagram of the compound of formula 1 of embodiment 1;
- Figure 2 is a schematic diagram of the asymmetric structural unit of the oxalate single crystal of the compound of formula 1 in Example 1;
- Fig. 3 is the XRPD spectrum of the sulfate of the compound of formula 1 in Example 2;
- Fig. 4 is the XRPD spectrum of the phosphate of the compound of formula 1 in Example 2;
- Fig. 5 is the XRPD spectrum of the isethionate of the compound of formula 1 in Example 2;
- Fig. 6 is the XRPD spectrum of the ⁇ -naphthalene sulfonate of the compound of formula 1 in Example 2;
- Fig. 7 is the XRPD spectrum of the L-malate salt of the compound of formula 1 in Example 2;
- Fig. 9 is the XRPD spectrum of the dihydrochloride salt of the compound of formula 1 in Example 4.
- FIG. 10 is the XRPD pattern of the fumarate salt of the compound of formula 1 in Example 5.
- sodium methoxide methanol solution (30 wt%, 50.32 g) was added to methanol (900 mL) at 20 °C, then the temperature was raised to 70 °C, and dimethyl malonate (461.12 g) and ethyl crotonate ( 349.46g) mixed uniformly, added dropwise to the methanol solution of sodium methoxide, and reacted at 70° C. for 3 hours.
- reaction solution was cooled to 10°C, adjusted to pH 3-4 with 3M hydrochloric acid, 500 mL of ethyl acetate was added, filtered with suction, the filter cake was washed with ethyl acetate (600 mL), separated, and saturated aqueous sodium bicarbonate solution (100 mL) was added. ), washed, separated, and concentrated the organic phase to obtain 26.89 g of pale yellow liquid.
- reaction solution was cooled to 0°C, 100 mL of ethyl acetate was added, the pH was adjusted to 7-8 with saturated sodium bicarbonate solution, extracted with ethyl acetate (50 mL ⁇ 3), and the organic phase was evaporated under reduced pressure to obtain The yellow solid 13.89g was used directly in the next step.
- Reaction conditions a) tert-butyl 2,5-diazabicyclo[4.1.0]heptane-2-carboxylate, N-methylpyrrolidone, 4-dimethylaminopyridine;
- AKT1 (Item #01-101, Carna)
- AKT2 (Item #01-102, Carna)
- AKT3 (Catalog #PV3185, Invitrogen)
- 1 mL of kinase AKT1, 2, 3 in 1 ⁇ kinase reaction buffer contains 200 ⁇ L of 5 ⁇ kinase reaction buffer, 5 ⁇ L of 1M MgCl 2 , 1 ⁇ L of 1 M DTT, and 794 ⁇ L of ultrapure water.
- the concentrations used in enzyme screening are shown in Table 1. Prepare 5X enzyme working solution with 1X Kinase Reaction Buffer.
- the europium-labeled tyrosine kinase substrate antibody was diluted 100-fold with detection reaction buffer as a working solution.
- Inhibition rate (ER positive control- ER sample )/(ER positive control- ER negative control ) ⁇ 100%
- the salt formation results are shown in the following table, wherein the salt formation type is determined by XRPD, and the molar ratio of the free base of the compound of formula 1 to the acid radical (ie the molar ratio of the cation of the compound of formula 1 to the acid radical in the salt) is determined by 1 HNMR.
- Figures 3 to 7 provide the XRPD patterns of sulfate, phosphate, isethionate, ⁇ -naphthalenesulfonate, and L-malate, respectively.
- the compound of formula 1 (2 g) and toluene (10 mL) were added to a 20 mL glass vial, and the solution was dissolved by shaking at room temperature.
- the clear solution was added to a 100 mL double-layer glass-jacketed reaction kettle, and a 4 mol/L hydrogen chloride ethyl acetate solution (0.99 mL) was added to the reaction kettle, and the reaction was stirred for 15 minutes.
- n-heptane (40 mL) was added to the reaction kettle, and the mixture was stirred and aged at room temperature for 2 hours. After the aging was completed, suction filtration, and the wet filter cake was dried under vacuum at 40° C. for 19 hours to obtain 1.97 g of the monohydrochloride of the compound of formula 1 in the form of a white solid powder.
- the XRPD pattern of the monohydrochloride salt of the compound of formula 1 is shown in FIG. 8 .
- the compound of formula 1 (2 g) and toluene (10 mL) were added to a 100 mL double-layer glass-jacketed reactor, and the solution was stirred at room temperature.
- a 4 mol/L hydrogen chloride ethyl acetate solution (2.18 mL) was added to the reaction kettle, and the reaction was stirred for 15 min.
- n-heptane (40 mL) was added to the reaction kettle, and the mixture was stirred and aged at room temperature for 4 hours. After the aging was completed, suction filtration, and the wet cake was dried under vacuum at 40° C. for 6 hours to obtain 2.25 g of the dihydrochloride of the compound of formula 1 in the form of a white solid powder.
- the XRPD pattern of the dihydrochloride salt of the compound of formula 1 is shown in FIG. 9 .
- the compound of formula 1 (25 mg) and isopropanol (1 mL) were added to a 3 mL glass vial, and the solution was stirred magnetically at room temperature.
- solid fumaric acid (6.31 mg) and the reaction was magnetically stirred at room temperature.
- n-heptane (2 mL) was added to a 3 mL glass vial and stirring was continued for 18 hours. After suction filtration, the wet cake was dried under vacuum at 40° C. for 3 hours to obtain the fumarate salt of the compound of formula 1 as a white solid powder.
- the XRPD pattern of the fumarate salt of the compound of formula 1 is shown in FIG. 10 .
- the compound of formula 1 of the present application has an inhibitory effect on AKT kinase activity, so the pharmaceutically acceptable salts of the compound of formula 1 of the present application, such as fumarate, methanesulfonate , isethionate, ⁇ -naphthalenesulfonate, p-toluenesulfonate, 1,2-ethanedisulfonate, oxalate, maleate, citrate, succinate, L-( +)-tartrate, hippurate, L-ascorbate, L-malate, benzoate, gentisate and monohydrochloride, dihydrochloride, sulfate, phosphate, etc.
- the pharmaceutically acceptable salts of the compound of formula 1 of the present application such as fumarate, methanesulfonate , isethionate, ⁇ -naphthalenesulfonate, p-toluenesulfonate, 1,2-ethanedis
- the pharmaceutically acceptable salts of the compounds of formula 1 of the present application can be used for the prevention and/or treatment of AKT protein kinase-mediated diseases or disease states, It can further be used to prepare a medicament for preventing and/or treating AKT protein kinase-mediated diseases or disease states.
- the pharmaceutically acceptable salt of the compound of formula 1 of the present application has higher stability than the compound of formula 1, improves the physicochemical properties of the compound of formula 1, and is beneficial to production and application.
Abstract
Description
Claims (15)
- 根据权利要求1所述的盐,其选自富马酸盐或盐酸盐。
- 根据权利要求1所述的盐,其中式1化合物与有机酸的摩尔比为1:1。
- 根据权利要求1所述的盐,其中式1化合物与氯化氢的摩尔比为1:1或1:2。
- 根据权利要求1所述的盐,其中式1化合物与氯化氢的摩尔比为1:2。
- 根据权利要求1所述的盐,选自富马酸盐,式1化合物与富马酸的摩尔比为1:1。
- 权利要求1-6中任一项所述的式1化合物的药学上可接受的盐的制备方法,包括式1化合物与相应的酸成盐的步骤。
- 根据权利要求7所述的方法,其中,成盐反应的溶剂选自醇类溶剂与烷烃类溶剂的混合溶剂、酮类溶剂与烷烃类溶剂的混合溶剂、酯类溶剂与烷烃类溶剂的混合溶剂、苯类溶剂与烷烃类溶剂的混合溶剂或卤代烃类溶剂与烷烃类溶剂的混合溶剂。
- 包含权利要求1-6任一项所述盐的药物组合物。
- 用作药物的权利要求1-6中任一项所述的式1化合物的药学上可接受的盐或权利要求9所述的药物组合物。
- 权利要求1-6任一项所述的盐或权利要求9所述的药物组合物用于预防和/或治疗AKT蛋白激酶介导的疾病或疾病状态的用途。
- 权利要求1-6任一项所述的盐或权利要求9所述的药物组合物在制备用于预防和/ 或治疗AKT蛋白激酶介导的疾病或疾病状态的药物中的用途。
- 根据权利要求11或12所述的用途,其中所述AKT蛋白激酶介导的疾病或疾病状态为癌症,优选乳腺癌、前列腺癌或卵巢癌,更优选前列腺癌。
- 一种预防和/或治疗AKT蛋白激酶介导的疾病或疾病状态的方法,其包括向有需要的个体给予权利要求1-6任一项所述的盐或权利要求9所述的药物组合物。
- 根据权利要求14所述的方法,其中,所述AKT蛋白激酶介导的疾病或疾病状态为癌症,优选乳腺癌、前列腺癌或卵巢癌,更优选前列腺癌。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21846285.1A EP4186902A1 (en) | 2020-07-22 | 2021-07-22 | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
CA3186568A CA3186568A1 (en) | 2020-07-22 | 2021-07-22 | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
US18/017,422 US20230286979A1 (en) | 2020-07-22 | 2021-07-22 | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
JP2023504144A JP2023535702A (ja) | 2020-07-22 | 2021-07-22 | ジヒドロピリド[2,3-d]ピリミジノン誘導体の塩、その調製方法及び用途 |
AU2021314419A AU2021314419B2 (en) | 2020-07-22 | 2021-07-22 | Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof |
CN202180049183.4A CN115836069B (zh) | 2020-07-22 | 2021-07-22 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010711260.5 | 2020-07-22 | ||
CN202010711260 | 2020-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022017449A1 true WO2022017449A1 (zh) | 2022-01-27 |
Family
ID=79728514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/107815 WO2022017449A1 (zh) | 2020-07-22 | 2021-07-22 | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230286979A1 (zh) |
EP (1) | EP4186902A1 (zh) |
JP (1) | JP2023535702A (zh) |
CN (1) | CN115836069B (zh) |
AU (1) | AU2021314419B2 (zh) |
CA (1) | CA3186568A1 (zh) |
WO (1) | WO2022017449A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882347A (zh) * | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
CN101511842A (zh) | 2006-07-06 | 2009-08-19 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶 |
CN101578273A (zh) | 2006-07-06 | 2009-11-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 |
CN101631778A (zh) | 2006-07-06 | 2010-01-20 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶 |
CN101970415A (zh) | 2008-01-09 | 2011-02-09 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
CN102574852A (zh) * | 2009-10-23 | 2012-07-11 | 伊莱利利公司 | Akt抑制剂 |
WO2020156437A1 (zh) * | 2019-01-29 | 2020-08-06 | 南京正大天晴制药有限公司 | Akt抑制剂 |
-
2021
- 2021-07-22 CA CA3186568A patent/CA3186568A1/en active Pending
- 2021-07-22 AU AU2021314419A patent/AU2021314419B2/en active Active
- 2021-07-22 US US18/017,422 patent/US20230286979A1/en active Pending
- 2021-07-22 CN CN202180049183.4A patent/CN115836069B/zh active Active
- 2021-07-22 JP JP2023504144A patent/JP2023535702A/ja active Pending
- 2021-07-22 WO PCT/CN2021/107815 patent/WO2022017449A1/zh unknown
- 2021-07-22 EP EP21846285.1A patent/EP4186902A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1882347A (zh) * | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
CN101511842A (zh) | 2006-07-06 | 2009-08-19 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的二氢呋喃并嘧啶 |
CN101578273A (zh) | 2006-07-06 | 2009-11-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的羟基化和甲氧基化的环戊二烯并[d]嘧啶 |
CN101631778A (zh) | 2006-07-06 | 2010-01-20 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的环戊二烯并[d]嘧啶 |
CN101970415A (zh) | 2008-01-09 | 2011-02-09 | 阵列生物制药公司 | 作为AKT蛋白激酶抑制剂的5H-环戊二烯并[d]嘧啶 |
CN102574852A (zh) * | 2009-10-23 | 2012-07-11 | 伊莱利利公司 | Akt抑制剂 |
WO2020156437A1 (zh) * | 2019-01-29 | 2020-08-06 | 南京正大天晴制药有限公司 | Akt抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
CA3186568A1 (en) | 2022-01-27 |
AU2021314419A1 (en) | 2023-03-23 |
CN115836069A (zh) | 2023-03-21 |
US20230286979A1 (en) | 2023-09-14 |
AU2021314419A8 (en) | 2023-03-30 |
AU2021314419B2 (en) | 2023-12-07 |
CN115836069B (zh) | 2024-02-06 |
EP4186902A1 (en) | 2023-05-31 |
JP2023535702A (ja) | 2023-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI828712B (zh) | 作為trk抑制劑的雜環化合物 | |
EP3294742B1 (en) | New (5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h)quinazolin-2-yl)-(1h-pyrazol-5-yl)-amines and theri derivatives as igf-1r/1r inhibitors. | |
TWI624447B (zh) | 吡咯衍生物的結晶及其製造方法 | |
MX2010010018A (es) | Nuevos derivados de carbazol inhibidores de hsp90, composiciones que los contienen y su uso. | |
CN109721600B (zh) | 一类含氮稠环化合物及其制备方法和用途 | |
EP3466958B1 (en) | New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof | |
FR2959510A1 (fr) | Derives de pyrido[3,2-d]pyrimidine, leurs procedes de preparation et leurs utilisations therapeutiques | |
FR2941948A1 (fr) | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src | |
TW202241902A (zh) | 一種嘧啶并五元氮雜環類衍生物的晶型及其製備方法 | |
CN114269723B (zh) | 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法 | |
WO2022017449A1 (zh) | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途 | |
CZ2016816A3 (cs) | Krystalické formy 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrilu s kyselinou fosforečnou a způsob jejich přípravy | |
EP3511333B1 (en) | Crystal form and salt form of 7h-pyrrolo[2,3-d]pyrimidine compound and preparation method therefor | |
WO2022017448A1 (zh) | 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐及晶型 | |
CN106146525B (zh) | 三并环类间变性淋巴瘤激酶抑制剂 | |
WO2022017446A1 (zh) | Akt抑制剂的单位剂量组合物 | |
CZ299700B6 (cs) | Krystalová modifikace C kyseliny 8-kyano-1-cyklopropyl-7-(1S, 6S-2,8-diazabicyklo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolinkarboxylové, zpusob její výroby a její použití | |
WO2021228223A1 (zh) | 氘代akt激酶抑制剂 | |
WO2023011428A1 (zh) | Ripk1抑制剂的晶型及其酸式盐和其酸式盐的晶型 | |
CN106083817A (zh) | 吡非尼酮衍生物及其制备方法 | |
TW201722960A (zh) | 經取代的氨基吡喃衍生物之晶型 | |
KR20230051207A (ko) | Jak 억제제의 염 형태, 결정형, 이의 제조방법 및 이의 용도 | |
WO2019085860A1 (zh) | Fgfr4抑制剂晶型及其制备方法 | |
TW202408483A (zh) | 一種硼酸酯衍生物的可藥用鹽、其結晶形式及用途 | |
CN116917287A (zh) | 异喹啉酮类化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21846285 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3186568 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023504144 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021846285 Country of ref document: EP Effective date: 20230222 |
|
ENP | Entry into the national phase |
Ref document number: 2021314419 Country of ref document: AU Date of ref document: 20210722 Kind code of ref document: A |